About Us

About VycellixTM, Inc.

Vycellix, Inc. is a private, immuno-centric discovery life science company, advancing the development of transformational platform technologies to enhance and optimize next-generation cell & gene-based therapies, including T cell and Natural Killer (NK) cell-based cancer therapies.

The Company’s platforms include:

  • VY-UC to generate immune-privileged universal cells without altering the components that control self-recognition (HLA), obviating the need for immune-suppressive drugs in contexts of allogeneic cell therapies, hence redefining “off-the-shelf” treatment strategies
  • VY-OZ to significantly enhance gene transduction rates and modify cells for immunotherapies and beyond
  • VY-M to accelerate expansion of cells, including immune cells, resulting in shorter “vein-to-vein” delivery time of new cell therapies to patients
  • VY-X to amplify serial tumor-killing capacity of T cells and NK cells via the selective upregulation of cytotoxic mechanisms

Karolinska Institutet & NextGenNK

Vycellix’s platforms were all discovered by scientists at the world-renowned Karolinska Institutet (KI) in Stockholm, Sweden. The Company is a collaborative partner in “NextGenNK”, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.

Goals Expectations